HeartBeam, a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to for treating cardiovascular disease, priced its IPO of 2.75 million units, each consisting of a share and one warrant to purchase a share at $6. The warrants are exercisable for five years after the issuance date.
The underwriters have an option to purchase an additional 412,500 shares and a like number of warrants .
The company’s stock and warrants list on the Nasdaq and are expected to begin trading today under BEAT and BEATW.
The offering is expected to close Nov. 15.
Heartbeam is developing ECG telemedicine technology to redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting. Read more.
